6879 Stock Overview
TCI GENE Inc. provides precision preventive medicines in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
TCI GENE Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$84.20 |
| 52 Week High | NT$134.50 |
| 52 Week Low | NT$76.50 |
| Beta | 0.20 |
| 1 Month Change | 3.95% |
| 3 Month Change | -3.55% |
| 1 Year Change | -30.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6879 | TW Healthcare | TW Market | |
|---|---|---|---|
| 7D | 8.6% | -2.1% | -0.6% |
| 1Y | -30.7% | -11.3% | 29.2% |
Return vs Industry: 6879 underperformed the TW Healthcare industry which returned -11.3% over the past year.
Return vs Market: 6879 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 6879 volatility | |
|---|---|
| 6879 Average Weekly Movement | 4.3% |
| Healthcare Industry Average Movement | 3.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6879 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6879's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.genext.me |
TCI GENE Inc. provides precision preventive medicines in Taiwan. It offers genetic testing for nutrient metabolism and weight management; G2 and ACE2 genetic testing; supplements; skin care, antiaging, kids’ growth, and Alzheimer disease products; and serum for DNA types. The company also provides nutrition consultation services.
TCI GENE Inc. Fundamentals Summary
| 6879 fundamental statistics | |
|---|---|
| Market cap | NT$2.23b |
| Earnings (TTM) | NT$11.67m |
| Revenue (TTM) | NT$333.86m |
190.9x
P/E Ratio6.7x
P/S RatioIs 6879 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6879 income statement (TTM) | |
|---|---|
| Revenue | NT$333.86m |
| Cost of Revenue | NT$159.24m |
| Gross Profit | NT$174.62m |
| Other Expenses | NT$162.94m |
| Earnings | NT$11.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 52.30% |
| Net Profit Margin | 3.50% |
| Debt/Equity Ratio | 0% |
How did 6879 perform over the long term?
See historical performance and comparison